Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
about
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomasSimultaneous imaging of membrane antigen and the corresponding chromosomal locus in pathology archives.FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene.Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.
P2860
Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Comparison between immunohisto ...... HER-2 status in breast cancer.
@ast
Comparison between immunohisto ...... HER-2 status in breast cancer.
@en
Comparison between immunohisto ...... HER-2 status in breast cancer.
@nl
type
label
Comparison between immunohisto ...... HER-2 status in breast cancer.
@ast
Comparison between immunohisto ...... HER-2 status in breast cancer.
@en
Comparison between immunohisto ...... HER-2 status in breast cancer.
@nl
prefLabel
Comparison between immunohisto ...... HER-2 status in breast cancer.
@ast
Comparison between immunohisto ...... HER-2 status in breast cancer.
@en
Comparison between immunohisto ...... HER-2 status in breast cancer.
@nl
P2093
P2860
P1476
Comparison between immunohisto ...... HER-2 status in breast cancer.
@en
P2093
Danica Jovanović
Dragica Nikolić-Vukosavljević
Natasa Todorović-Raković
Zora Nesković-Konstantinović
P2860
P304
P356
10.1111/J.1440-1827.2005.01831.X
P577
2005-06-01T00:00:00Z